Osteosarcoma typically arises in tissues of mesenchymal origin, and is the most malignant bone tumor characterized by high local aggressiveness, with poor therapeutic outcome. Busulfan has been widely used to treat CML. So far, there are no reports on the therapeutic effect of busulfan on osteosarcoma. Here, we showed that busulfan dose-dependently reduced the cell viability and proliferation, and induced cell apoptosis, senescence, and reactive oxygen species levels in two osteosarcoma cell lines. Moreover, a series of loss-of-function and gain-of-function experiments further indicated that busulfan may have its anti-osteosarcoma effect by upregulating the microRNA-200 (miR-200) family which subsequently downregulated its target genes ZEB1 and ZEB2. Furthermore, treatment with busulfan potentially inhibited the growth of implanted osteosarcoma in nude mice. Taken together, our data suggest that busulfan may have an anti-osteosarcoma effect through downregulating ZEB1 and ZEB2 through activating the miR-200 family, highlighting a possibility of using busulfan as a novel therapy for osteosarcoma.
Osteosarcoma is the most common primary malignancy to arise from bone. The pathogenesis of osteosarcoma is unclear, and new therapy molecular target is needed. The miRNAs researched suggested that miRNAs are involved in the pathogenesis of osteosarcoma. MiR-141, which belong to miR-200 family, take a part in tumorigenesis. However, the role of miR-141 in the pathogenesis of osteosarcoma remained unclear. In this study, we focused on the miR-141 in osteosarcoma and found that the expression of miR-141 is lower in osteosarcoma. Overexpression of miR-141 not only inhibits osteosarcoma cell proliferation but also induces cell apoptosis. It is estimated that miR-141 played its role via ZEB1 and ZEB2. In all, miR-141 played a osteosarcoma-suppressing role via ZEB1 and ZEB2. Our finding may elucidate the miRNAs mechanism in osteosarcoma and provide a new molecule target for osteosarcoma therapy.
Osteosarcoma is the 3rd most common human cancer in childhood and young adults, and is the leading cause of mortality. Recent studies suggest that miRNAs could regulate the growth and progression of osteosarcoma, indicating some novel targets for therapy. In our study, we demonstrated that miR-451 was down-regulated in human osteosarcoma U2OS, SAOS, and MG63 cells lines as well as in tumor tissue surgically resected compared with the normal tissues. Overexpression of miR-451 inhibited cell proliferation and resulted in cell apoptosis in osteosarcoma cells. G1 cell cycle arrest was also induced by miR-451. Repressed by miR-451, PGE2 and CCND1 reversed the inhibitory effects of miR-451 on proliferation. In conclusion, miR-451 played a tumor-suppressing role through modulating the expression of PGE2 and CCND1, suggesting a novel target for the diagnosis and treatment of osteosarcoma.
Matrix metalloproteinases (MMPs) have been known to play a pivotal role in the age- and/or disease-related degradation of intervertebral discs. We aimed to explore as to whether the expression of these enzymes is correlated to disc degeneration caused by increasing age and severity of herniation in the East Asian population. Thus, we studied the expressions of MMP-1 (collagenase), MMP-2 (gelatinase) and MMP-14 (membrane-type protease) in 65 patients diagnosed with lumbar disc herniation. The patients were divided into 3 groups according to their age, and the severity of herniation was graded on the basis of magnetic resonance imaging (MRI). Immunohistochemistry analysis was conducted to determine the expression of different MMPs in the post-surgery disc specimens. The results showed that expressions of these three enzymes were directly and positively related to the degree of disc degradation. Whereas, the MMP-1 expression was found to be elevated with the increasing age, the MMP-2 and MMP-14 remained unchanged in groups of different ages. A direct correlation between the expressions of MMP-2 and MMP-14 suggested a role of MMP-14 in the modulation of MMP-2 expression.
Immunostaining for epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3, c-erbB-4, ER, and PR was performed in 107 cases of primary breast carcinomas from Anyang, China. The expression rates of EGFR, c-erbB-2, c-erbB-3 and c-erbB-4 in this series were 43.9%, 36%, 27%, and 45.8%, respectively, and a stronger c-erbB-4 staining of "normal" glandular structures inside tumors and in the vicinity of tumor clusters was confirmed. Larger tumor size, lymph node metastases, and higher histologic grade in invasive ductal carcinomas were shown to be statistically valuable negative prognostic factors, and c-erbB-2 expression was also weakly associated with a poor prognosis no matter what the nodal status. The expressions of c-erbB-4 and ER in invasive ductal carcinomas were inversely associated with histologic grade of the tumors. Associations between the expression of c-erbB-4 and ER (p = 0.001) and the expression of ER and PR study (p = 0.004) were found in the present study. No significant associations between the expressions of EGFR, c-erbB-3, c-erbB-4, ER, and PR and overall survival were detected. The expression of c-erbB-4 in the node negative group was, however, associated with a better prognosis, indicating a different role of c-erbB-4 protein in breast tumor development than other EGFR family members have. Int J Surg Pathol 9(3):177-187, 2001
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.